Navigation Links
InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
Date:10/28/2008

BRITISH COLUMBIA, Canada, Oct. 28 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that Jeff Morhet, CEO and Chairman, will present at the 7th Annual BIO Investor Forum on October 30, 2008.

Mr. Morhet's thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform, recent partnerships and company milestones.

The 7th Annual BIO Investor Forum will be held October 29-31, 2008 at the Palace Hotel in San Francisco, California. The BIO Investor Forum is held every year to bring late-stage private and emerging public biotech companies and investors together to meet and attend roundtables, panel discussions and seminars on a variety of biotechnology topics.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. InNexus Biotechnology Strengthens Patent Team With New Leadership
5. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
9. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
10. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
11. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... three months ended December 31, 2016. SQI ... diagnostics company that develops and commercializes proprietary technologies and products ... ... commercial milestones achieved in fiscal 2016," said Andrew Morris ...
(Date:2/21/2017)... ... ... The medical potential of stem cells is both extensive and astounding, and ... their differentiating characteristics. Stem cells are unique as the have the potential to renew ... tissue or organic-specific cells with special functions. , Stem cell therapy in the ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... to announce that it has been approved for full, active membership in the ... Dallas, Texas, was founded by Chief Executive Officer Jeff Olson in ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
Breaking Biology News(10 mins):